Bayesian Model comparison of Higgs couplings

We investigate the possibility of contributions from physics beyond the Standard Model (SM) to the Higgs couplings, in the light of the LHC data. The work is performed within an interim framework where the magnitude of the Higgs production and decay rates are rescaled though Higgs coupling scale factors. We perform Bayesian parameter inference on these scale factors, concluding that there is good compatibility with the SM. Furthermore, we carry out Bayesian model comparison on all models where any combination of scale factors can differ from their SM values and find that typically models with fewer free couplings are strongly favoured. We consider the evidence that each coupling individually equals the SM value, making the minimal assumptions on the other couplings. Finally, we make a comparison of the SM against a single "not-SM" model, and find that there is moderate to strong evidence for the SM.Comment: 24 pages, 4 figure

Running of Neutrino Parameters and the Higgs Self-Coupling in a Six-Dimensional UED Model

We investigate a six-dimensional universal extra-dimensional model in the extension of an effective neutrino mass operator. We derive the \beta-functions and renormalization group equations for the Yukawa couplings, the Higgs self-coupling, and the effecive neutrino mass operator in this model. Especially, we focus on the renormalization group running of physical parameters such as the Higgs self-coupling and the leptonic mixing angles. The recent measurements of the Higgs boson mass by the ATLAS and CMS collaborations at the LHC as well as the current three-flavor global fits of neutrino oscillation data have been taken into account. We set a bound on the six-dimensional model, using the vacuum stability criterion, that allows five Kaluza-Klein modes only, which leads to a strong limit on the cutoff scale. Furthermore, we find that the leptonic mixing angle \theta_{12} shows the most sizable running, and that the running of the angles \theta_{13} and \theta_{23} are negligible. Finally, it turns out that the findings in this six-dimensional model are comparable with what is achieved in the corresponding five-dimensional model, but the cutoff scale is significantly smaller, which means that it could be detectable in a closer future.Comment: 14 pages, 3 figures. Final version published in Phys. Lett.

Effects of intermediate scales on renormalization group running of fermion observables in an SO(10) model

In the context of non-supersymmetric SO(10) models, we analyze the renormalization group equations for the fermions (including neutrinos) from the GUT energy scale down to the electroweak energy scale, explicitly taking into account the effects of an intermediate energy scale induced by a Pati--Salam gauge group. To determine the renormalization group running, we use a numerical minimization procedure based on a nested sampling algorithm that randomly generates the values of 19 model parameters at the GUT scale, evolves them, and finally constructs the values of the physical observables and compares them to the existing experimental data at the electroweak scale. We show that the evolved fermion masses and mixings present sizable deviations from the values obtained without including the effects of the intermediate scale.Comment: Comments: 20 pages, 3 figures. Final version published in JHE

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years